Amarin Corporation PLC
First Floor, Block 3
The Oval<br>Shelbourne Road
303 articles with Amarin Corporation PLC
With the J.P. Morgan Healthcare Conference winding down, companies remain busy striking deals and informing investors about pipeline advances. BioSpace snagged some of the interesting news bits to come out of the conference from Wednesday.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Amarin Corporation - AMRN
Pomerantz LLP is investigating claims on behalf of investors of Amarin Corporation plc ("Amarin" or the "Company") (NASDAQ: AMRN). Such investors are advised to contact Robert S. Willoughby at email@example.com or 888-476-6529, ext. 9980.
Clinical data for a fish-oil-based drug from Amarin Corporation PLC confirmed the drug’s ability to reduce the relative risk reduction of adverse cardiovascular events by 25 percent, including a 20 percent reduction in cardiovascular death.
Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stroke Demonstrated in REDUCE-IT™ Supports 25% Overall Reduction in Five-Point Major Adverse Cardiovascular Event
Landmark Cardiovascular Risk Reduction Benefits Demonstrated in REDUCE-IT Are Largest of Any Major Cardiovascular Outcomes
Physicians have long recommended fish oil to patients with high cholesterol and triglycerides, even though the scientific studies on it are mixed. Amarin developed a drug called Vascepa, which derives from a purified component of fish oil called eicosapentaenoic acid (EPA).
As we move into the last quarter of 2018, plenty of companies are looking at potential catalysts. George Budwell, writing for The Motley Fool, takes a look at three potentially high-reward biotech companies, but along with their big catalysts comes high risk.
In addition, Amarin has granted the underwriter a 30-day option to purchase approximately $10.5 million of additional ADSs.
On January 26, 2018, the last sale price of the ADSs on The NASDAQ Global Market was $4.27 per share.
1/23/2018Patients are being scheduled for final study visits commencing March 1, 2018. Amarin maintains its guidance to report top-line results from the study before the end of Q3 2018.
Under the parties' February 2015 agreement, Eddingpharm is responsible for Vascepa development, regulatory activities, commercialization and associated costs, including managing and funding this pivotal registration study.
Amarin plans to discuss these results and expectations with investors in connection with the 36th Annual J.P. Morgan Healthcare Conference.
Amarin: Real World Data Analysis Shows That Persistent Hypertriglyceridemia Despite Statin Therapy is Associated With Cardiovascular Risk
This analysis of RWE is separate from and independent of the RWE analysis referenced in Amarin’s press release on November 12, 2017.
Amarin: Vascepa (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipid and Inflammatory Markers in Statin Treated Patients With Persistent High Triglycerides and Chronic Kidney Disease
This oral presentation was held at the American Heart Association (AHA) 2017 Scientific Sessions in Anaheim, California.
Amarin Corporation: Real-World Data Analysis Shows That High Triglyceride Levels Are Associated With Increased Cardiovascular Events and Medical Costs
The analysis was presented at the 2017 American Heart Association (AHA) Scientific Sessions in Anaheim, CA.
Net product revenue in the third quarter of 2017 achieved record levels.
The conference call will follow the anticipated release of the company's financial results earlier that day.
Amarin's REDUCE-IT Cardiovascular Outcomes Study Of Vascepa To Continue As Planned At Recommendation Of Independent Data Monitoring Committee